Cytomegalovirus (CMV) also known as HCMV, or Human Herpesvirus 5 (HHV-5) is the virus most commonly transmitted to a developing fetus. It is a common virus that infects people of all ages. According to the CDC, over half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms. Whereas when a baby is born with cytomegalovirus (CMV) infection, it is called congenital CMV. Each year, approximately 5,000 infants in the U.S. may develop permanent problems due to CMV, some of the severe problems, includes deafness, blindness, and mental retardation. Furthermore, the global prevalence of congenital cytomegalovirus is said to be 0.3 – 2.0%. The Institute of Medicine (IOM) of the National Academy of Sciences, has designated CMV as a “highest priority” category for vaccine development, citing the years of life and disability that could be saved.
This report contains market size and forecasts of Cytomegalovirus (CMV) Vaccine in global, including the following market information:
Global Cytomegalovirus (CMV) Vaccine Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Cytomegalovirus (CMV) Vaccine Market Sales, 2017-2022, 2023-2028, (K Doses)
Global top five Cytomegalovirus (CMV) Vaccine companies in 2021 (%)
The global Cytomegalovirus (CMV) Vaccine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Attenuated Vaccines Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cytomegalovirus (CMV) Vaccine include Merck, AlphaVax, Moderna and Novartis, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cytomegalovirus (CMV) Vaccine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cytomegalovirus (CMV) Vaccine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Doses)
Global Cytomegalovirus (CMV) Vaccine Market Segment Percentages, by Type, 2021 (%)
Attenuated Vaccines
Subunit Vaccines
Global Cytomegalovirus (CMV) Vaccine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Doses)
Global Cytomegalovirus (CMV) Vaccine Market Segment Percentages, by Application, 2021 (%)
Laboratories
Hospitals
Diagnostic Centers and Clinics
Others
Global Cytomegalovirus (CMV) Vaccine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Doses)
Global Cytomegalovirus (CMV) Vaccine Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cytomegalovirus (CMV) Vaccine revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Cytomegalovirus (CMV) Vaccine revenues share in global market, 2021 (%)
Key companies Cytomegalovirus (CMV) Vaccine sales in global market, 2017-2022 (Estimated), (K Doses)
Key companies Cytomegalovirus (CMV) Vaccine sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
AlphaVax
Moderna
Novartis